Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Choreo LLC

Choreo LLC cut its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 8.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 3,714 shares of the biopharmaceutical company’s stock after selling 321 shares during the period. Choreo LLC’s holdings in Regeneron Pharmaceuticals were worth $2,619,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in REGN. Atomi Financial Group Inc. boosted its position in shares of Regeneron Pharmaceuticals by 4.9% during the third quarter. Atomi Financial Group Inc. now owns 575 shares of the biopharmaceutical company’s stock worth $605,000 after buying an additional 27 shares during the period. Daymark Wealth Partners LLC boosted its position in shares of Regeneron Pharmaceuticals by 20.3% during the third quarter. Daymark Wealth Partners LLC now owns 355 shares of the biopharmaceutical company’s stock worth $373,000 after buying an additional 60 shares during the period. CWM LLC boosted its position in shares of Regeneron Pharmaceuticals by 1.1% during the third quarter. CWM LLC now owns 2,272 shares of the biopharmaceutical company’s stock worth $2,389,000 after buying an additional 25 shares during the period. Wedmont Private Capital boosted its position in shares of Regeneron Pharmaceuticals by 4.5% during the third quarter. Wedmont Private Capital now owns 1,496 shares of the biopharmaceutical company’s stock worth $1,490,000 after buying an additional 65 shares during the period. Finally, Adirondack Trust Co. boosted its position in shares of Regeneron Pharmaceuticals by 2.4% during the third quarter. Adirondack Trust Co. now owns 431 shares of the biopharmaceutical company’s stock worth $453,000 after buying an additional 10 shares during the period. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Trading Up 0.7 %

Shares of NASDAQ REGN opened at $722.07 on Friday. The stock has a market cap of $79.35 billion, a price-to-earnings ratio of 17.87, a PEG ratio of 1.60 and a beta of 0.08. The business has a 50 day simple moving average of $717.27 and a 200 day simple moving average of $914.93. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 5.28. Regeneron Pharmaceuticals, Inc. has a 52 week low of $642.00 and a 52 week high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, topping the consensus estimate of $11.21 by $0.86. The company had revenue of $3.79 billion during the quarter, compared to the consensus estimate of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 33.61% and a return on equity of 16.88%. The company’s revenue for the quarter was up 10.3% compared to the same quarter last year. During the same period in the previous year, the firm posted $11.86 earnings per share. On average, research analysts predict that Regeneron Pharmaceuticals, Inc. will post 37.75 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, March 20th. Investors of record on Thursday, February 20th will be paid a $0.88 dividend. This represents a $3.52 annualized dividend and a dividend yield of 0.49%. The ex-dividend date is Thursday, February 20th.

Analyst Ratings Changes

Several brokerages recently commented on REGN. Piper Sandler dropped their target price on Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an “overweight” rating on the stock in a report on Monday, January 27th. Wolfe Research began coverage on Regeneron Pharmaceuticals in a report on Friday, November 15th. They set an “outperform” rating and a $1,150.00 target price on the stock. Morgan Stanley dropped their target price on Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating on the stock in a report on Friday, November 1st. Leerink Partnrs raised Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Wednesday. Finally, TD Cowen dropped their target price on Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a “buy” rating on the stock in a report on Tuesday. One research analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have issued a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $973.13.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.